Log in to save to my catalogue

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acu...

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acu...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1913399189

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

About this item

Full title

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

Publisher

London: Nature Publishing Group UK

Journal title

Leukemia, 2018-01, Vol.32 (1), p.30-37

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring
DNA methyltransferase 3A-
R882H/-R882C mutations (
DNMT3A
mut
). MRD was determined by real-time quantitative PCR (RQ-PCR) in 1494 samples of 181
DNMT3A
mut
patients. At the time of diagnosis,
DN...

Alternative Titles

Full title

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1913399189

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1913399189

Other Identifiers

ISSN

0887-6924

E-ISSN

1476-5551

DOI

10.1038/leu.2017.200

How to access this item